Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 6/20 | 0.47 |
| ▸ | CHRNA3 | P32297 | 6/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7427405 | 0.82 | CHRNB2 (0.45) | CHRNB2CHRNA3 | |
| SCHEMBL7424304 | 0.81 | CHRNB2 (0.40) | CHRNB2CHRNA3 | |
| SCHEMBL7421696 | 0.81 | CHRNB2 (0.40) | CHRNB2CHRNA3 | |
| SCHEMBL7421694 | 0.81 | CHRNB2 (0.40) | CHRNB2CHRNA3 | |
| Hydrochloric Acid SCHEMBL7426872 | 0.81 | CHRNB2 (0.44) | CHRNB2CHRNA3 | |
| Hydrochloric Acid SCHEMBL7419320 | 0.80 | CHRNB2 (0.39) | CHRNB2CHRNA3 | |
| Hydrochloric Acid SCHEMBL7419323 | 0.80 | CHRNB2 (0.39) | CHRNB2CHRNA3 | |
| SCHEMBL7994340 | 0.78 | CHRNB2 (0.49) | CHRNB2CHRNA3HRH3 | |
| SCHEMBL7423822 | 0.72 | CHRNB2 (0.50) | CHRNB2CHRNA3 | |
| SCHEMBL7423827 | 0.72 | CHRNB2 (0.50) | CHRNB2CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120028931-A1 | HETEROCYCLIC M-GLU5 ANTAGONISTS | RECORDATI IRELAND LIMITED (IE) | 2012-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028931-A1 | HETEROCYCLIC M-GLU5 ANTAGONISTS | OPRM1, GRM5, OPRD1 | CHRNB2 83/4885CHRNA3 27/4885HRH3 140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.